CHF24.95
20.16% yesterday
SIX Swiss Exchange, Nov 15, 05:31 pm CET
ISIN
CH0325814116
Symbol
KURN
Sector
Industry

Kuros Biosciences Stock price

CHF24.95
+1.95 8.48% 1M
+16.95 211.88% 6M
+21.46 614.90% YTD
+21.49 621.10% 1Y
+22.93 1,135.15% 3Y
+22.18 800.72% 5Y
+5.48 28.13% 10Y
SIX Swiss Exchange, Closing price Fri, Nov 15 2024
-6.30 20.16%
ISIN
CH0325814116
Symbol
KURN
Sector
Industry

Key metrics

Market capitalization CHF1.17b
Enterprise Value CHF1.17b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 22.18
P/S ratio (TTM) P/S ratio 22.35
P/B ratio (TTM) P/B ratio 19.27
Revenue growth (TTM) Revenue growth 157.23%
Revenue (TTM) Revenue CHF52.54m
EBIT (operating result TTM) EBIT CHF-4.92m
Free Cash Flow (TTM) Free Cash Flow CHF-3.25m
EPS (TTM) EPS CHF-0.24
P/S forward 15.21
EV/Sales forward 15.10
Show more

Is Kuros Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Kuros Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Kuros Biosciences:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Kuros Biosciences:

Buy
100%

Financial data from Kuros Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
53 53
157% 157%
100%
- Direct Costs 7.20 7.20
63% 63%
14%
45 45
183% 183%
86%
- Selling and Administrative Expenses 41 41
98% 98%
78%
- Research and Development Expense 6.87 6.87
39% 39%
13%
-2.30 -2.30
76% 76%
-4%
- Depreciation and Amortization 2.62 2.62
7% 7%
5%
EBIT (Operating Income) EBIT -4.92 -4.92
60% 60%
-9%
Net Profit -8.89 -8.89
44% 44%
-17%

In millions CHF.

Don't miss a Thing! We will send you all news about Kuros Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals, and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment offers Fibrin-PTH, a drug-biologic combination which promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The Legacy portfolio segment is involved in all other products that do not belong to the group's core business strategy. The company was founded by Didier Cowling in 2000 and is headquartered in Schlieren, Switzerland.

Head office Switzerland
CEO Christopher Fair
Employees 5
Founded 2000
Website kurosbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today